Trial Profile
A Multiple Dose Study With Increasing Pramipexole Doses (0.375 mg to 4.5 mg q.d.) of Oral Extended Release (ER) Tablets With a Three-way Cross Comparison of 4.5 mg Pramipexole ER q.d. Fasted Versus 4.5 mg Pramipexole ER q.d. Fed Versus 1.5 mg Pramipexole Immediate Release Tablets t.i.d. Fasted in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Oct 2014
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary)
- Indications Gilles de la Tourette's syndrome; Myoclonus; Parkinson's disease; Restless legs syndrome
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 15 Oct 2014 New trial record